Arcadia Investment Management Corp MI Reduces Holdings in Becton, Dickinson and Company (NYSE:BDX)

Arcadia Investment Management Corp MI trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 22.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,011 shares of the medical instruments supplier's stock after selling 8,477 shares during the period. Becton, Dickinson and Company comprises 1.2% of Arcadia Investment Management Corp MI's investment portfolio, making the stock its 27th largest position. Arcadia Investment Management Corp MI's holdings in Becton, Dickinson and Company were worth $6,645,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares in the last quarter. Hara Capital LLC grew its holdings in shares of Becton, Dickinson and Company by 26.4% in the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock worth $76,000 after purchasing an additional 70 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $21,607,000. Callan Family Office LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $299,000. Finally, Edgestream Partners L.P. bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $1,255,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Barclays lowered their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $219.22.

Insider Buying and Selling

In other news, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Up 1.0%

Shares of NYSE BDX opened at $174.60 on Wednesday. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The company has a market cap of $50.04 billion, a price-to-earnings ratio of 33.32, a PEG ratio of 1.31 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock has a 50-day moving average price of $172.66 and a two-hundred day moving average price of $206.96.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. Becton, Dickinson and Company's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.17 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.38%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.